Table 2.
Summary of trial procedures
| Study visit day | Within 4 weeks Baseline |
Day 0 | Week 26 ±14days |
Week 52 (12 months) ±14 days |
| Description of visit | Screening | Baseline | First follow-up | Final visit |
| Informed consent | X | |||
| Review eligibility | X | X | ||
| Demographic data* | X | |||
| Antiretroviral/medical history | X | X | X | X |
| Healthcare utilisation data† | X | X | X | |
| Silver Clinic consultation (intervention arm only) | X | X | X | |
| Usual care (control arm) | X | X | X | |
| Frailty measures‡ | X | X | X | |
| PRO§ | X | X | X |
*Comorbidities, time since HIV diagnosis, duration living with HIV, CD4, viral load, number of non-ART medications, number of falls in last 6 months.
†Number of referrals to primary, secondary and social care.
‡Fried frailty phenotype measure, FRAIL scale, Timed Up and Go test, Rockwood clinical frailty scale, Montreal Cognitive Assessment.
§Patient-reported outcomes (PRO) as HIV PROM, EuroQol, Adult Social Care Outcomes Toolkit, Client Service Receipt inventory, Consultation and Relational Empathy.